glp 1 ibd Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential Effects of GLP-1 receptor agonist

When the dust settles

The weight loss market is undergoing a seismic shift as the focus moves from injectable peptides to oral small molecule GLP-1 receptor agonists, led by Eli Lillys promising candidate, orforglipron

Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to a FAIR Health white paper entitled, Obesity and GLP-1 Drugs: A Claims-Based Analysis

8 fully disclosed ingredients no fillers, no blends

Despite Polycystic Ovary Syndrome (PCOS) is a very prevalent disorder among women of reproductive age, there is widespread agreement that until now, no pharmacological options are available to tackle the entire spectrum of clinical manifestations encountered in the clinical practice

FDA updates rules on compounded GLP-1 drugs, impacting patients and providers